Abstract
Gene therapy provides the possibility of long term treatment for the severest of congenital disorders. In this review we will examine the recent advances in gene therapy for genodermatoses. Congenital diseases of the skin exhibit a wide range of severity and underlying causes and there are many possible therapeutic avenues. Gene therapy approaches can follow three paths-in vivo, ex vivo and fetal gene therapy, though the later is currently theoretical only it can provide potential results for even the most severe congenital diseases. All approaches utilize the many different vector systems available, including viral and the emerging use of non- viral integrating vectors. In addition, the use of RNAi based techniques to prevent dominant mutant protein expression has been explored as a therapy for specific dominant disorders such as keratin mutation disorders. Progress has been rapid in the past few years with some initial successful clinical trials reported. However, there are still some issues surrounding long term expression, transgene sustainability and safety issues that need to be addressed to further shift from experimental to clinically therapeutic applications. With the continuing development, merger and refinement of existing techniques there is an ever increasing likelihood of gene therapies becoming available for the more severe genodermatoses within the next decade or shortly thereafter.
Current Gene Therapy
Title: Current Advances in Gene Therapy for the Treatment of Genodermatoses
Volume: 9 Issue: 6
Author(s): Heather A. Long, James R. McMillan, Hongjiang Qiao, Masashi Akiyama and Hiroshi Shimizu
Affiliation:
Abstract: Gene therapy provides the possibility of long term treatment for the severest of congenital disorders. In this review we will examine the recent advances in gene therapy for genodermatoses. Congenital diseases of the skin exhibit a wide range of severity and underlying causes and there are many possible therapeutic avenues. Gene therapy approaches can follow three paths-in vivo, ex vivo and fetal gene therapy, though the later is currently theoretical only it can provide potential results for even the most severe congenital diseases. All approaches utilize the many different vector systems available, including viral and the emerging use of non- viral integrating vectors. In addition, the use of RNAi based techniques to prevent dominant mutant protein expression has been explored as a therapy for specific dominant disorders such as keratin mutation disorders. Progress has been rapid in the past few years with some initial successful clinical trials reported. However, there are still some issues surrounding long term expression, transgene sustainability and safety issues that need to be addressed to further shift from experimental to clinically therapeutic applications. With the continuing development, merger and refinement of existing techniques there is an ever increasing likelihood of gene therapies becoming available for the more severe genodermatoses within the next decade or shortly thereafter.
Export Options
About this article
Cite this article as:
Long A. Heather, McMillan R. James, Qiao Hongjiang, Akiyama Masashi and Shimizu Hiroshi, Current Advances in Gene Therapy for the Treatment of Genodermatoses, Current Gene Therapy 2009; 9 (6) . https://dx.doi.org/10.2174/156652309790031139
DOI https://dx.doi.org/10.2174/156652309790031139 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry Structural Key Genes: Differentiating Lung Squamous Cell Carcinomas from Adenocarcinomas
Current Bioinformatics Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry MRI Evaluation Using DWI and T2WI of Residual Lymph Nodes in patients Affected by Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
Current Medical Imaging MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry HPV Viral Activity by mRNA-HPV Molecular Analysis to Screen the Transforming Infections in Precancer Cervical Lesions
Current Pharmaceutical Biotechnology The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Radiochemotherapy for Non Small Cell Lung Cancer
Current Drug Therapy The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Role of Cell Cycle Biomarkers in Human Papillomavirus Related Uterine Lesions
Current Pharmaceutical Design Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Proteomic Signatures for Cancer Personalized Medicine)
Current Proteomics Editorial
Reviews on Recent Clinical Trials